PHARMACEUTICAL COMPANIES IN ITALY

FACTS & FIGURES



THE FRONT LINE AGAINST COVID-19

About **200 VACCINES** are **UNDER DEVELOPMENT** worldwide, including
45 already at the clinical trial phase.

Many companies are engaged on **R&D** for Covid-19 therapies, vaccines and diagnostic tests.

Sector donations to help manage the crisis now total almost \$ 750m.

Pharmaceutical companies In **Italy** have so far contributed € 41 m towards crisis management. They have also donated medicinal products, goods and services and are promoting **initiatives to assist** patients, doctors and staff in all healthcare sectors. Many companies have modified their production lines in order to meet health requirements and disinfectant demand - often transferring them gratuitously.

And in so doing they have guaranteed a **perfectly safe operational continuity** thereby ensuring access to therapies for patients and the maintenance of full employment for the industry.

OUR STRENGTH, OUR PERSONNEL

66,500 persons work in the pharmaceutical industry and 146 thousand in allied industries. In the last 5 years employment has risen at a higher rate than in the other sectors (10% vs the overall economy average of 5%), thanks to the industry's dynamism and its sustainable and inclusive growth models.

Gender equality is a fact: 43% of the personnel are women (compared to the industrial average of

29%), and many occupy important management positions.

Many measures have been taken to sustain **parenthood**, on top of state-mandated assistance.

Training and professional development are widespread, driven by the high demand for transversal and soft skills.

Over the past 5 years the proportion of **young people** has increased constantly: the under-35s have risen by **16%** and, overall, 80% are in an open-ended employment relationship.

Welfare is tailored to the **needs of persons**, as illustrated by the use of long-standing smart working methods as well as by the valorisation of **diversity**, training, **health** and prevention, **assistance to families**, the elderly and the disabled.

UNITED IN THE FIGHT AGAINST THE CLIMATE CRISIS

The pharmaceutical industry is fully committed to ecological transition.

Major investments are constantly improving environmental compliance and the efficient management of **resources**: water treatment, lower levels of waste and plastic use.

In the past ten years, in Italy, the sector has abated energy consumption by 48% and cut greenhouse gas emissions by 50%: which is more than the industrial average.

These results stem from ever greater investment in **green technologies**. The proportion allocated to pollution prevention

(either total elimination or abatement at source) amounts to 44%, compared to a manufacturing average of 37%.

The "circular approach" generates innovation, increases efficiency and competitiveness and benefits not only the companies but also the environment and the communities in the territories where they operate.

A VALUE FOR THE COUNTRY AND PEOPLE'S HEALTH

With a production value of € 34 bn,

the pharmaceutical industry in Italy is a strategic asset for the economy. Moreover, together with Germany, it is a European leader whose exports have grown by 168% over the last ten years (against the EU average of 86%).

Each year registers a new record in **R&D** investments: € **1.6 bn** (7 % of the total for Italy and 30% higher than in 2013), of which **over € 700 m** dedicated to **clinical research**, of which the greater part earmarked for NHS facilities. Together

with $\[\]$ 1.4 bn for production, investments in the country have reached 3 bn.

In the next 5 years the pharmaceutical companies will invest over \$ 1,500 bn

worldwide in R&D: an opportunity for **growth and development** that Italy, with its many excellences can seize by implementing good business policies.

This is an objective within the country's grasp: participating in ever-more targeted and effective research on the **16 thousand therapies under development in the world** designed to cure or "chronicize" hitherto life-threatening diseases, avoid hospitalization and prevent or arrest the course of pathologies.

MEMBER COMPANIES

A.C.R.A.F. Aziende Chimiche Riunite Angelini Francesco | A. Menarini Ind. Farm. Riunite | Abbvie | Abiogen Pharma | Acarpia Farmaceutici | Adare Pharmaceuticals | Addenda Pharma | Advanced Accelerator Applications Italy | Aeffe Farmaceutici | Aerosol Service Italiana | Aesculapius Farmaceutici | Aesica Pharmaceuticals | Alfa Biotech | Alfasigma | Alk-Abelló | Allergan | Alliance Pharma | Almirall | Altergon Italia | Amgen | Amuchina | Aptuit | Astellas Pharma | Astrazeneca | Avara Liscate Pharmaceutical Services | Bausch & Lomb Iom | Bayer Healthcare Manufacturing | Bayer | Biogen Italia | Biologici Italia Laboratories | Biopharma | Biotest Italia | Boehringer Ingelheim Italia | Bracco Imaging Italia | Bristol -Myers Squibb | Bruschettini | Bsp Pharmaceuticals C.O.C. | Farmaceutici | Catalent Italy | Celgene | Chiesi Farmaceutici | Corden Pharma Latina | Corden Pharma | Cosmo | Crucell Italy | CSO Pharmitalia | Daiichi Sankyo Italia | Dompé Farmaceutici | Doppel Farmaceutici | Ecupharma | Eisai | Eli Lilly Italia | E-Pharma Trento | Euromed | F.I.R.M.A. | Famar Italia | Farmaceutici Damor | Farmaka | Farmalabor | Farmila-Thea Farmaceutici | Farmitalia Ind. Chimico Farmac. | Fatro | Ferring | Fine Foods & Pharmaceuticals N.T.M. | Galderma Italia | Galileo Research | Gb Pharma | Ge Healthcare | Gentium | Gilead Sciences Srl | Giuliani | L Glaxosmithkline Manufacturing | Glaxosmithkline | Glaxosmithkline Vaccines | Grifols Italia | Grünenthal Italia | Guerbet | Hikma Italia | L.B.I. Giovanni Lorenzini | I.B.N. Savio | I.Bir.N. - Ist. Bioterapico Naz. | Ibsa Farmaceutici Italy | Ice Rende |

Idi Farmaceutici | Ipsen | IQVIA les Italy | Ist. Farm. Biologico Stroder | Istituto De Angeli | Istituto Ganassini | Istituto Gentili | Istituto Luso Farmaco d'Italia I Italchimici | Italfarmaco | Itel Telecomunicazioni | Janssen-Cilag | Johnson & Johnson Medical | Kedrion | Kyowa Kirin | L. Molteni & C. F.lli Alitti | Lab. it. Biochim. Farm.co Lisapharma | Laboratori Baldacci | Laboratori Guidotti | Laboratorio Farmaceutico C.T. | Laboratorio Farmaceutico S.I.T. | Laboratorio Terapeutico M.R. | Leo Pharma | Lepetit | Lifepharma | Lofarma | Lundbeck Italia | Malesci Istituto Farm. | Mastelli | Master Pharma | Merck Serono | Mergurio Pharma | Mitim | Monico | Msd Italia | Mundipharma Pharmaceuticals | Mylan Italia | Neopharmed Gentili | Nerviano Medical Sciences | Noos | Norgine Italia | Novartis Farma | Novo Nordisk | Octapharma Italy | Omikron Italia | Organon Italia | Otsuka Pharmaceutical Italy | Patheon Italia | Pfizer Holding Italy | Pfizer Italia | Pfizer | Pharmafar | Pharmanutra | Philogen | Piam Farmaceutici | Pierre Fabre Pharma | Pierrel | Polichem | Polifarma | Promedica | Recordati Ind.Chim.Farm. | Recordati Rare Diseases Italy | Roche | Sanofi | Savio Pharma Italia | Scharper | Servier Italia | Shionogi | Sifi | Simesa | So.Se.Pharm | Società Prodotti Antibiotici | Sofar | Stewart Italia | Takeda Italia | Temmler Italia | Teva Italia | Therabel Gienne Pharma | Tubilux Pharma | Ucb Pharma I Valeas Ind.Chimica e Farmac. I Valpharma International | ViiV Healthcare | Visufarma | Welcome Pharma | Wyeth Lederle | 7ambon | 7eta Farmaceutici

FARMINDUSTRIA

Largo del Nazareno 3/8 - 00187 Rome

T: +39 06 675801

Avenue de la Joyeuse Entrée 1 - B1040 Brussels

T: +32 2 2861255

farmindustria@farmindustria.it www.farmindustria.it











